GET DAILY SIGNALSOmeros Corporation (OMER) Q3 2026 Earnings: Tracking Progress on the YARTEMLEA Launch
Key Takeaways
- Omeros Corporation (NASDAQ: OMER) is scheduled to report third-quarter 2026 financial results after the market closes on Monday, November 16, 2026, followed by a conference call at 4:30 p.m. Eastern Time.
- Consensus estimates point to revenue of roughly $37 million, a meaningful step up from $28.5 million in the second quarter, as YARTEMLEA's commercial launch matures.
- Earnings per share (EPS) expectations are clustered near breakeven at approximately $0.02, compared with a net loss in the same quarter a year earlier.
- Investors will focus on YARTEMLEA (narsoplimab) prescription trends, gross-to-net pricing dynamics, operating cash flow, and the company's cash runway.
- Pipeline updates across the MASP-2 franchise and the OMS805 program represent potential additional catalysts beyond the quarterly numbers.
Why This Quarter Matters
Omeros Corporation's third-quarter 2026 report marks the company's third full quarter since the January 2026 U.S. commercial launch of YARTEMLEA, its first approved product for transplant-associated thrombotic microangiopathy (TA-TMA), a rare and serious blood-clotting complication that can follow stem cell transplants. This quarterly update is a key checkpoint for investors assessing whether the launch can sustain its early trajectory after second-quarter net sales more than doubled sequentially. Because OMER has historically reported losses, the report also offers an important read on the pace of its transition toward profitability and its ability to fund operations from product revenue rather than external capital.
Earnings Forecasts
Heading into the November 16 release, Wall Street consensus forecasts revenue of approximately $37 million for the third quarter, up from $28.5 million in net sales reported for the second quarter of 2026. EPS estimates are clustered near breakeven at roughly $0.02 per share, though individual analyst estimates range from a small loss to a modest profit, reflecting continued uncertainty around launch uptake and expense timing. For context, Omeros reported a net loss in the same quarter a year earlier, before YARTEMLEA was on the market. On a generally accepted accounting principles (GAAP) basis, results can swing sharply because of non-cash fair-value adjustments on financial instruments, so investors are likely to focus on adjusted figures and underlying product sales. The company has not issued formal revenue guidance, citing limited visibility into prescribing trends. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Sentiment Heading Into the Report
Sentiment into the third-quarter print has been shaped by the strong second-quarter beat, which saw net sales of $28.5 million far exceed expectations and sent shares higher. That backdrop raises the bar for this report, as investors look for evidence that YARTEMLEA adoption is broadening across transplant centers rather than plateauing. Key risk factors heading into earnings include any slowdown in new account growth, an unexpected rise in gross-to-net deductions from chargebacks and distribution fees, or softer-than-expected commentary on cash burn. Because the stock has shown elevated volatility around recent reports, a revenue miss or cautious forward commentary could weigh on shares even if headline EPS lands near breakeven.
What to Watch After the Numbers
Following the report, investors should watch management's commentary on YARTEMLEA's commercial trajectory, including the number of ordering accounts and any signs of repeat prescribing. Gross-to-net pricing — the gap between list prices and realized revenue after chargebacks and distribution fees — remains a critical metric for judging revenue quality, and management has previously indicated this could drift slightly higher as government-program participation expands.
Cash generation and liquidity will also be in focus. The company ended the second quarter with roughly $132 million in cash and investments and has said it expects to fund operations for more than 12 months. Updates on operating expense trends, particularly research and development (R&D) spending tied to the OMS805 program, will help clarify the path toward sustained profitability.
Beyond the numbers, investors should monitor pipeline milestones across the MASP-2 franchise and potential regulatory or reimbursement developments for YARTEMLEA. Management has signaled multiple value-driving milestones over the next 18 months, making the post-earnings call an important source of forward-looking signals even without formal revenue guidance. From what I see, this is important because it could shape the longer-term outlook for the company.
Integrating AI Tools Into Earnings Analysis
In my regular research process, I turn to Tickeron's AI Screener to quickly filter opportunities and compare names like OMER against peers on technical and fundamental metrics. It helps surface ideas efficiently when preparing for reports like this one, allowing me to focus on the details that matter most for the quarter ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
OMER in downward trend: 10-day moving average moved below 50-day moving average on October 20, 2026
The 10-day moving average for OMER crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 58 cases where OMER's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.
OMER moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OMER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for OMER entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OMER's RSI Indicator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on November 11, 2026. You may want to consider a long position or call options on OMER as a result. In 74 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for OMER just turned positive on November 11, 2026. Looking at past instances where OMER's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.
Following a +8.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where OMER advanced for three days, in 217 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
OMER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.853) is normal, around the industry mean (3.498). P/E Ratio (8.812) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (35.714) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 11 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. OMER’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 39 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of pharmaceutical products
Industry Biotechnology
Advertisement